Striking a new path – extending the diagnostic portfolio by test systems for therapeutic drug monitoring - EUROIMMUNBlog
Mechanism of action of anti-tumor necrosis factor biologics and... | Download Scientific Diagram
The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease
Mechanisms of action of anti-TNF biologics. Anti-TNF biologics bind and... | Download Scientific Diagram
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling | Gut
Frontiers | The TNF Paradox in Cancer Progression and Immunotherapy | Immunology
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation - Clinical Gastroenterology and Hepatology
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls | Immunotherapy
Tumor Necrosis Factor (TNF) Inhibitors | SpringerLink
TNFa 억제제 비교 etanercept, adalimumab, infliximab, certolizumab, tanfanercept HL036 : 네이버 블로그
Indication extrapolation for anti-TNF biosimilars | Nature Reviews Gastroenterology & Hepatology
Anti-TNF therapy | Musculoskeletal Key
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls | Immunotherapy
Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology | Semantic Scholar
Use of Biologic Agents in the Treatment of Uveitis
Cureus | Biologic Therapies in Sarcoidosis and Uveitis: A Review
Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF | Annals of the Rheumatic Diseases
Structure (A); and mechanisms of action (B) of anti-TNF biologics. All... | Download Scientific Diagram
Internet Scientific Publications
Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists - ScienceDirect
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists | Journal of Pharmacology and Experimental Therapeutics
Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist?
Frontiers | Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology | Immunology
Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor
TNF Inhibitor - an overview | ScienceDirect Topics
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
